Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation

Performing an in vivo shRNA screen, Zhang et al. identify that CHD1 loss confers antiandrogen resistance. Low CHD1 levels correlate with shorter clinical responses to enzalutamide. CHD1 loss induces global chromatin changes, increasing expression of transcription factors that contribute to antiandrogen resistance.

from Cancer Cell https://ift.tt/3aoRMdG